AIDS Research and Therapy (Sep 2021)
Expanding access to HIV services during the COVID-19 pandemic—Nigeria, 2020
- Andrew T. Boyd,
- Ibrahim Jahun,
- Emilio Dirlikov,
- Stacie Greby,
- Solomon Odafe,
- Alhassan Abdulkadir,
- Olugbenga Odeyemi,
- Ibrahim Dalhatu,
- Obinna Ogbanufe,
- Andrew Abutu,
- Olugbenga Asaolu,
- Moyosola Bamidele,
- Chibuzor Onyenuobi,
- Timothy Efuntoye,
- Johnson O. Fagbamigbe,
- Uzoma Ene,
- Ayodele Fagbemi,
- Nguhemen Tingir,
- Chidozie Meribe,
- Adeola Ayo,
- Orji Bassey,
- Obinna Nnadozie,
- Mary Adetinuke Boyd,
- Dennis Onotu,
- Jerry Gwamna,
- McPaul Okoye,
- William Abrams,
- Matthias Alagi,
- Ademola Oladipo,
- Michelle Williams-Sherlock,
- Pamela Bachanas,
- Helen Chun,
- Deborah Carpenter,
- David A. Miller,
- Ugonna Ijeoma,
- Anuli Nwaohiri,
- Patrick Dakum,
- Charles O. Mensah,
- Ahmad Aliyu,
- Bolanle Oyeledun,
- Prosper Okonkwo,
- John O. Oko,
- Akudo Ikpeazu,
- Gambo Aliyu,
- Tedd Ellerbrock,
- Mahesh Swaminathan
Affiliations
- Andrew T. Boyd
- Centers for Disease Control and Prevention, Division of Global HIV and TB, Center for Global Health
- Ibrahim Jahun
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Emilio Dirlikov
- Centers for Disease Control and Prevention, Division of Global HIV and TB, Center for Global Health
- Stacie Greby
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Solomon Odafe
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Alhassan Abdulkadir
- Maryland Global Initiatives Corporation, University of Maryland School of Medicine Nigeria Program
- Olugbenga Odeyemi
- Maryland Global Initiatives Corporation, University of Maryland School of Medicine Nigeria Program
- Ibrahim Dalhatu
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Obinna Ogbanufe
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Andrew Abutu
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Olugbenga Asaolu
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Moyosola Bamidele
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Chibuzor Onyenuobi
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Timothy Efuntoye
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Johnson O. Fagbamigbe
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Uzoma Ene
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Ayodele Fagbemi
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Nguhemen Tingir
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Chidozie Meribe
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Adeola Ayo
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Orji Bassey
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Obinna Nnadozie
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Mary Adetinuke Boyd
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Dennis Onotu
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Jerry Gwamna
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- McPaul Okoye
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- William Abrams
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Matthias Alagi
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Ademola Oladipo
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- Michelle Williams-Sherlock
- Centers for Disease Control and Prevention, Division of Global HIV and TB, Center for Global Health
- Pamela Bachanas
- Centers for Disease Control and Prevention, Division of Global HIV and TB, Center for Global Health
- Helen Chun
- Centers for Disease Control and Prevention, Division of Global HIV and TB, Center for Global Health
- Deborah Carpenter
- Centers for Disease Control and Prevention, Division of Global HIV and TB, Center for Global Health
- David A. Miller
- Centers for Disease Control and Prevention, Division of Global HIV and TB, Center for Global Health
- Ugonna Ijeoma
- Centers for Disease Control and Prevention, Division of Global HIV and TB, Center for Global Health
- Anuli Nwaohiri
- Centers for Disease Control and Prevention, Division of Global HIV and TB, Center for Global Health
- Patrick Dakum
- Institute of Human Virology (IHVN)
- Charles O. Mensah
- Institute of Human Virology (IHVN)
- Ahmad Aliyu
- Institute of Human Virology (IHVN)
- Bolanle Oyeledun
- Center for Integrated Health Program (CIHP)
- Prosper Okonkwo
- AIDS Prevention Initiative Nigeria (APIN)
- John O. Oko
- Catholic Caritas Foundation Nigeria (CCFN)
- Akudo Ikpeazu
- Federal Ministry of Health
- Gambo Aliyu
- National Agency for the Control of AIDS
- Tedd Ellerbrock
- Centers for Disease Control and Prevention, Division of Global HIV and TB, Center for Global Health
- Mahesh Swaminathan
- Centers for Disease Control and Prevention Nigeria, Division of Global HIV and TB, Center for Global Health
- DOI
- https://doi.org/10.1186/s12981-021-00385-5
- Journal volume & issue
-
Vol. 18,
no. 1
pp. 1 – 8
Abstract
Abstract Background To accelerate progress toward the UNAIDS 90-90-90 targets, US Centers for Disease Control and Prevention Nigeria country office (CDC Nigeria) initiated an Antiretroviral Treatment (ART) Surge in 2019 to identify and link 340,000 people living with HIV/AIDS (PLHIV) to ART. Coronavirus disease 2019 (COVID-19) threatened to interrupt ART Surge progress following the detection of the first case in Nigeria in February 2020. To overcome this disruption, CDC Nigeria designed and implemented adapted ART Surge strategies during February–September 2020. Methods Adapted ART Surge strategies focused on continuing expansion of HIV services while mitigating COVID-19 transmission. Key strategies included an intensified focus on community-based, rather than facility-based, HIV case-finding; immediate initiation of newly-diagnosed PLHIV on 3-month ART starter packs (first ART dispense of 3 months of ART); expansion of ART distribution through community refill sites; and broadened access to multi-month dispensing (MMD) (3–6 months ART) among PLHIV established in care. State-level weekly data reporting through an Excel-based dashboard and individual PLHIV-level data from the Nigeria National Data Repository facilitated program monitoring. Results During February–September 2020, the reported number of PLHIV initiating ART per month increased from 11,407 to 25,560, with the proportion found in the community increasing from 59 to 75%. The percentage of newly-identified PLHIV initiating ART with a 3-month ART starter pack increased from 60 to 98%. The percentage of on-time ART refill pick-ups increased from 89 to 100%. The percentage of PLHIV established in care receiving at least 3-month MMD increased from 77 to 93%. Among PLHIV initiating ART, 6-month retention increased from 74 to 92%. Conclusions A rapid and flexible HIV program response, focused on reducing facility-based interactions while ensuring delivery of lifesaving ART, was critical in overcoming COVID-19-related service disruptions to expand access to HIV services in Nigeria during the first eight months of the pandemic. High retention on ART among PLHIV initiating treatment indicates immediate MMD in this population may be a sustainable practice. HIV program infrastructure can be leveraged and adapted to respond to the COVID-19 pandemic.
Keywords